Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome

A phase 1 trial plans to be initiated in 2024 to investigate GTB-3650 for the treatment of patients with CD33-positive leukemia.

The FDA has granted accelerated approval to pirtobrutinib for the treatment of patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.

In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.

The biologics license application seeking the approval of obe-cel as a potential therapeutic option in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.

An investigational new drug application for TCB008 has been cleared by the FDA. A phase 1B trial will now assess the agent in patients with relapsed/refractory acute myeloid leukemia.